BridgeBio Pharma Dividends and Buybacks
Dividend criteria checks 0/6
BridgeBio Pharma does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-5.8%
Buyback Yield
Total Shareholder Yield | -5.8% |
Future Dividend Yield | 0% |
Dividend Growth | n/a |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
BridgeBio: Next Chapter Begins After Attruby Approval
Nov 24BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analysts Are More Bearish Than They Used To Be
Nov 19Revenues Not Telling The Story For BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Sep 24BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis
Aug 31BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon
Aug 17BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing
Jun 10BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)
Jun 03BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck
Jan 11Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if BBIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BBIO's dividend payments have been increasing.
Dividend Yield vs Market
BridgeBio Pharma Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (BBIO) | n/a |
Market Bottom 25% (US) | 1.4% |
Market Top 25% (US) | 4.4% |
Industry Average (Biotechs) | 2.4% |
Analyst forecast (BBIO) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate BBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate BBIO's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BBIO has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 16:32 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BridgeBio Pharma, Inc. is covered by 24 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
George Farmer | BMO Capital Markets Equity Research |
Konstantinos Biliouris | BMO Capital Markets Equity Research |
Jason Zemansky | BofA Global Research |